In this article, we will look at the 10 Fastest Growing NASDAQ Stocks to Buy.
High growth stocks have once again taken center stage, and major asset managers argue that earnings momentum remains the decisive factor. In its 2026 Year-Ahead Investment Outlook, J.P. Morgan Asset Management notes that “profit growth has been impressive, tracking for four consecutive quarters of double-digit earnings growth”. The firm adds that “within stocks, we continue to see the biggest opportunities in structural rather than cyclical stories”, underscoring a preference for companies benefiting from secular tailwinds. Artificial intelligence remains a major catalyst behind this structural growth. J.P. Morgan writes that “the investment and adoption of AI continues to dominate the strength seen in U.S. economic and earnings growth”.
Vanguard’s 2026 Economic and Market Outlook echoes this constructive stance on growth, stating that “U.S. technology stocks could well maintain their momentum given the rate of investment and anticipated earnings growth.” At the same time, Vanguard cautions that “risks are growing amid this exuberance,” highlighting the need for selectivity.
Taken together, these outlooks suggest that fast-growing companies with sustained revenue acceleration and clear structural drivers remain compelling. With growth serving as the engine of returns, the focus shifts to businesses capable of compounding at elevated rates rather than merely benefiting from earnings multiple expansion. Against this backdrop, we’ll look at the 10 Fastest Growing NASDAQ Stocks to Buy.
Our Methodology
We used the Finviz screener to identify NASDAQ stocks that have achieved more than 50% sales growth over the past year and more than 50% growth over the past three years. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
10. IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
On February 25, 2026, IDEAYA Biosciences, Inc. (NASDAQ:IDYA) announced that the first patient has been enrolled in its Phase 1 dose escalation and expansion trial evaluating IDE034, an investigational PTK7/B7H3 bispecific TOP1 ADC. The company plans to evaluate the safety, tolerability, and pharmacokinetics of IDE034 as a monotherapy in the Phase 1 study. It also intends to test combinations with agents targeting the DNA damage response pathway, including its proprietary PARG inhibitor IDE161. Dosing the first patient with IDE034 triggers a $5M milestone payment from Ideaya to Biocytogen under the companies’ option and license agreement.
On February 23, 2026, IDEAYA Biosciences announced the appointment of Theodora Ross to the newly created role of chief development officer. In this position, Ross will lead early clinical development for the company’s emerging oncology pipeline and help guide its long-term research and development strategy. Ross joins Ideaya from AbbVie, where she served as VP, head of early oncology R&D and site head for the Bay Area.
On February 17, 2026, IDEAYA Biosciences reported Q4 revenue of $10.88M, compared with consensus estimates of $5.95M. Collaboration revenue reflected performance obligations satisfied through December 31, 2025, related to research and development services recognized over time under the Servier exclusive license agreement for darovasertib. President and CEO Yujiro Hata said the company delivered “a strong quarter of clinical execution, clinical pipeline expansion and commercial readiness activities.” He cited highlights including completion of enrollment of 437 patients in the OptimUM-02 Phase 2/3 registrational trial, IND submissions for IDE034 and IDE574, and continued expansion of the company’s U.S. commercial organization ahead of upcoming topline progression-free survival results.
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
9. Eos Energy Enterprises, Inc. (NASDAQ:EOSE)
On February 27, 2026, Eos Energy Enterprises, Inc. (NASDAQ:EOSE) saw mixed analyst actions following recent results. Stifel lowered the firm’s price target on the shares to $12 from $22 and maintained a Buy rating. On the same day, Guggenheim analyst Joseph Osha downgraded the stock to Neutral from Buy and removed the firm’s prior $20 price target after the release of Q4 results and the company’s 2026 outlook. The analyst said the company is making operational progress and could be successful over time, but management’s struggles with financial forecasting and communication remain a “challenge for valuation.”
On February 26, 2026, Eos Energy reported Q4 EPS of (84c), compared with consensus estimates of (24c). The company posted Q4 revenue of $58.0M, below the $93.69M consensus estimate. CEO Joe Mastrangelo said 2025 represented “a structural turning point for Eos,” highlighting accelerated production, expanded annual capacity to 2 GWh, record quarterly revenue, a cash position above $600M, and more than $240M in Q4 bookings across diversified markets. Mastrangelo added that while the company was “disappointed in not meeting revenue expectations,” execution improved as the year progressed and the company exited 2025 with operational momentum. He said the focus in 2026 will be on disciplined scale and margin improvement, including manufacturing efficiency, improved unit economics, and converting backlog into revenue.
Eos Energy Enterprises, Inc. (NASDAQ:EOSE) designs, develops, manufactures, and markets energy storage solutions for utility-scale, microgrid, and commercial and industrial applications in the United States.
